Kymera Therapeutics KYMR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $51.48M-12.6% | $39.21M-16.7% | $43.73M-50.1% | $44.71M-49.5% | $58.89M-25.8% | ||
| $334.48M+23.1% | $316.57M+31.8% | $304.55M+37.6% | $290.87M+39.1% | $271.68M+38.8% | ||
| $72.27M+10.5% | $68.19M+7.3% | $67.58M+10.0% | $65.7M+9.3% | $65.43M+15.1% | ||
| —— | $3.86M-21.7% | $3.86M-21.7% | $0-100% | $0-100% | ||
| $410.6M+21.8% | $388.61M+25.9% | $375.99M+30.7% | $356.57M+30.1% | $337.12M+30.9% | ||
| $410.6M+21.8% | $388.61M+25.9% | $375.99M+30.7% | $356.57M+30.1% | $337.12M+30.9% | ||
| -$359.13M-29.1% | -$349.4M-33.5% | -$332.26M-66.0% | -$311.86M-68.0% | -$278.23M-56.3% | ||
| -697.7%-225pp | -891.1%-335pp | -759.7%-531pp | -697.5%-488pp | -472.5%-248pp | ||
| $44.12M+18.1% | $38.05M+0.7% | $37.14M+13.5% | $36.43M+31.4% | $37.35M+59.3% | ||
| -$315M-30.8% | -$311.35M-39.1% | -$295.12M-76.2% | -$275.43M-74.5% | -$240.88M-55.8% | ||
| -612%-203pp | -794.1%-318pp | -674.8%-484pp | -616%-438pp | -409.1%-214pp | ||
| -$3.58-15.1% | -$3.69-23.8% | -$3.60-53.8% | -$3.48-43.8% | -$3.11-23.9% | ||
| -$3.58-15.1% | -$3.69-23.8% | -$3.60-53.8% | -$3.48-43.8% | -$3.11-23.9% | ||
| 349.8M+14.9% | 332.4M+12.7% | 322.9M+16.0% | 311.8M+19.6% | 304.4M+23.8% | ||
| 349.8M+14.9% | 332.4M+12.7% | 322.9M+16.0% | 311.8M+19.6% | 304.4M+23.8% | ||
| -$319.14M-33.4% | -$308.07M-37.0% | -$295.55M-81.2% | -$273.06M-74.7% | -$239.16M-56.0% | ||
| $357K+41.7% | $368K+47.8% | $337K+39.3% | $299K+34.1% | $252K+20.0% | ||
| $44.48M+18.3% | $38.42M+1.0% | $37.47M+13.7% | $36.73M+31.4% | $37.6M+59.0% | ||
| $44.12M+18.1% | $38.05M+0.7% | $37.14M+13.5% | $36.43M+31.4% | $37.35M+59.3% | ||
| $51.48M-12.6% | $39.21M-16.7% | $43.73M-50.1% | $44.71M-49.5% | $58.89M-25.8% | ||
| -$359.13M-29.1% | -$349.4M-33.5% | -$332.26M-66.0% | -$311.86M-68.0% | -$278.23M-56.3% | ||
| -$350.84M-29.8% | -$341.09M-34.1% | -$323.99M-67.1% | -$303.76M-68.4% | -$270.27M-55.4% | ||
| -$350.84M-29.8% | -$341.09M-34.1% | -$323.99M-67.1% | -$303.76M-68.4% | -$270.27M-55.4% | ||
| -681.6%-223pp | -869.9%-330pp | -740.8%-519pp | -679.4%-476pp | -459%-240pp | ||
| -$359.13M-29.1% | -$349.4M-33.5% | -$332.26M-66.0% | -$311.86M-68.0% | -$278.23M-56.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kymera Therapeutics's revenue?
- Kymera Therapeutics (KYMR) generated $51.5M in revenue over the trailing twelve months, down 12.6% year over year.
- Is Kymera Therapeutics profitable?
- Kymera Therapeutics is not currently profitable: it reported a net loss of $315.0M over the trailing twelve months, a -612.0% net margin.
- What is Kymera Therapeutics's earnings per share?
- Kymera Therapeutics's diluted EPS over the trailing twelve months is $-3.58.
- Where does Kymera Therapeutics's income statement data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
